Kezar Life Sciences Inc KZR

$7.29 -0.07 (-0.95%)

Valuation

Market cap
53,856,000
Revenue TTM
$0
Net income TTM
$-56,030,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
616,000
Avg volume
96,874
Day's range
$7.27 – $7.47
Shares out
7,388,000
Stochastic %K
25%
Beta
0.40
Analysts
Hold
Price target
$6.00

Price

Company profile

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2...

Show more

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 822 5600
Website
https://www.kezarlifesciences.com
Address
4000 Shoreline Court, Suite 300, South San Francisco, United States

Latest news

Stocktwits

CEMBP_Trader Sep 10, 4:39 PM
$KZR First payout $0.478, which already covers the cost of the CVR plus some 🍀🏦🍀
1 replies
CEMBP_Trader May 13, 12:55 AM
$KZR Shares gone, cash and CVR received. Let’s see what the CVR can return. 🍀🎉🍀
0 replies
nsomniyak May 12, 2:49 AM
$KZR Here's the payout timeline as I understand it. $6.95 cash per share - to be paid promptly - probably this week or next. cash CVR - pro-rata share of KZR net cash above $50MM - probably 3-4 months as AUPH wil need to audit KZR financials drug-related CVR - out in the fture if/when KZR's drug reaches certain milestones
0 replies
nsomniyak May 12, 2:10 AM
$KZR The buyout of KZR by AUPH was approved.
0 replies
TwongStocks May 7, 2:28 PM
$KZR Equity Corporate Actions Alert #2026 - 307 Information Regarding the Tender Offer of Kezar Life Sciences, Inc. (KZR) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-307 The tender offer by Aurinia Pharmaceuticals Inc. $AUPH to acquire all of the outstanding common stock of Kezar Life Sciences, Inc. $KZR is scheduled to expire at 11:59 p.m. ET, on May 8, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on May 11, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 8, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 11th) and will be suspended effective May 12, 2026. KZR shareholders will receive $6.955 & one non-transferable CVR for each share held.
0 replies
whatsup58 Apr 23, 9:48 PM
$KZR this is officially done now?
0 replies
STACKD0E Apr 15, 4:13 PM
$RVMD $KZR 🙃✨
0 replies
focafoca99 Apr 3, 9:37 PM
$KZR is paying about $2 million to exit its San Francisco lease early, including a $1.3 million cash payment and the loss of its $0.7 million security deposit.
0 replies